MJU On Point Webinar: Moderator Luna Stower - Strategies, industry ambassador and legacy advocate

Panel: Wanda L. James - Candidate for US Congress, Ally Jubelier - Cannabis and Hemp Attorney, Meg Sanders - CEO of Canop Provisions, Shanita Penny - Executive Director for the Coalition for Cannabinoid Policy Education and Regulation

This episode originally aired on Jan 23, 2026

This conversation goes beyond headlines to explore the real impact of Cannabis rescheduling and why it may not benefit everyone equally. Rather than presenting Schedule 3 as a universal win, the panel breaks down the regulatory, financial, and strategic realities shaping the future of the industry.

You’ll learn how timelines, compliance demands, and legal uncertainty will influence operators, investors, researchers, and regulators—and why preparedness will determine who is positioned to succeed. The discussion offers a grounded look at how policy shifts unfold in practice, highlighting that rescheduling is not a simple solution, but a complex transition with uneven outcomes.

This panel unpacks the reality behind the proposed shift of Cannabis to Schedule 3 and what it truly means (and doesn’t mean).

Hear directly from operators on:

• Who benefits and who’s exposed

• Why this could take years, not months

• How pharma, FDA posture, and enforcement shape the outcome

🌿 5 Key Takeaways

1. Rescheduling is not a universal benefit

The shift to Schedule 3 will not “lift all boats”—outcomes will vary depending on resources, readiness, and positioning.

2. Prepared players have the advantage

Organizations with capital, infrastructure, and regulatory knowledge are best equipped to navigate and benefit from the changes.

3. Regulatory complexity remains a challenge

Ongoing uncertainty between federal and state frameworks continues to create barriers and risks.

4. Timelines are uncertain and may be prolonged

The rescheduling and implementation process is not immediate, requiring long-term planning and adaptability.

5. Outcomes differ across stakeholders

Operators, investors, researchers, and regulators will each experience distinct opportunities and challenges.

⚠️ What’s Missing for the Patient

While this conversation explains how the system may shift, it does not address how patient care may improve.

Here’s what wasn’t covered:

• Access pathways remain unclear

There is no discussion on how patients will obtain Cannabis under a Schedule 3 framework.

• Patient costs are not addressed

Increased compliance and regulation may impact affordability, but this is not explored.

• No guidance for physicians

The role of healthcare providers in recommending or prescribing Cannabis is left unaddressed.

• The Endocannabinoid System is absent

The biological foundation for how Cannabis works in the body is not included in the discussion.

• Patient outcomes are not prioritized

There is no focus on symptom relief, quality of life, or real-world health improvements.

🧠 Final Insight

This conversation explains who may benefit from the shift —

but not how patients will.

And that gap is where education, advocacy, and the future of healthcare must step in.

A note from the Editors: The perspectives shared are those of the panelists and do not necessarily reflect the views of the Effective Cannabis Newsletter (ECN). While Schedule III has not yet been enacted into law, understanding its potential impact is critical for patients navigating their health and care.

About MJU On Point Webinars:

MJU On Point, a dynamic webinar series from MJ Unpacked that brings the thought leadership and actionable Cannabis business insights of our national Cannabis tradeshow events directly to your screen.

Click the Learn More Button